Neratinib +/- Fulvestrant in HER2+, ER+ Metastatic Breast Cancer

NCT03289039 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

21

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Breast Cancer

Interventions

DRUG: Neratinib
DRUG: Fulvestrant

Sponsor

Dana-Farber Cancer Institute

Collaborators

[object Object]